Table 1

Demographics and clinical characteristics of the COVID-19 Global Rheumatology Vaccine Survey respondents who received COVID-19 vaccination (n=2860)

Number of respondents N (%)
Age (years), mean (SD)55.3 (14.3)
Age (years) categories
 18–29139 (4.9)
 30–49788 (27.6)
 50–691336 (46.7)
 70+469 (16.4)
Sex at birth
 Female2480 (86.7)
 Male373 (13.0)
 Other/Prefer not to say7 (0.2)
Race/Ethnicity
 White2469 (86.3)
 Hispanic, Latinx or Latin American77 (2.7)
 Asian (South, East Asian)46 (1.6)
 Black37 (1.3)
 Middle Eastern or North African21 (0.7)
 American Indian/laska Natives/Aboriginal/Indigenous/First Nations7 (0.2)
 Other*203 (7.1)
WHO region
 Region of the Americas1603 (56.1)
 European region1187 (41.5)
 Western Pacific/South-East Asian/African/Eastern Mediterranean regions70 (2.4)
Educational level
 High school (secondary level)/General Educational Development (GED) or less314 (11.0)
 Some college553 (19.3)
 Bachelor’s degree (graduated college)776 (27.1)
 Graduate or professional degree1217 (42.6)
Systemic rheumatic disease diagnosis†
 Rheumatoid arthritis1209 (42.3)
 Inflammatory myositis487 (17.0)
 Sjögren’s syndrome438 (15.3)
 Systemic lupus erythematosus391 (13.7)
 Spondyloarthritis, other than psoriatic arthritis256 (9.0)
 Psoriatic arthritis206 (7.2)
 Other connective tissue disease‡196 (6.9)
 Systemic vasculitis167 (5.8)
 Systemic sclerosis126 (4.4)
 Antiphospholipid syndrome68 (2.4)
 Autoinflammatory disease31 (1.1)
 Sarcoidosis21 (0.7)
Medications†
Systemic glucocorticoids762 (26.6)
NSAIDs740 (25.9)
DMARDs
 Antimalarials733 (25.6)
 Methotrexate855 (29.9)
 Other csDMARDs§513 (17.8)
 Mycophenolate mofetil228 (8.0)
 Other antimetabolites¶21 (0.7)
 Abatacept71 (2.5)
 Rituximab162 (5.7)
 TNF inhibitors498 (17.2)
 Other bDMARDs**206 (7.2)
 JAK inhibitors121 (4.2)
 IVIG102 (3.6)
Number of DMARDs
 0520 (18.2)
 11271 (44.4)
 2839 (29.3)
 3 or more230 (8.0)
Patient global assessment of disease activity (0=very low; 10=very high)
 Mean (SD)4.2 (2.4)
Comorbidities
 Hypertension912 (31.9)
 Lung disease††736 (25.7)
 Obesity672 (23.5)
 Diabetes164 (5.7)
 Cardiovascular disease163 (5.7)
 None832 (29.1)
COVID-19 vaccine received
 Pfizer-BioNTech1522 (53.2)
 Oxford-AstraZeneca645 (22.6)
 Moderna610 (21.3)
 Janssen/Johnson & Johnson50 (1.7)
 Other vaccines‡‡33 (1.2)
  • *Other participants include Pacific Islander, other, prefer not to say and do not know/unsure.

  • †Participants may indicate more than one rheumatic disease and more than one antirheumatic medication.

  • ‡Other connective tissue disease include mixed connective tissue disease and undifferentiated connective tissue disease.

  • §Includes apremilast, azathioprine, 6-mercaptopurine, leflunomide, sulfasalazine.

  • ¶Includes calcineurin inhibitors (ciclosporin, tacrolimus), cyclophosphamide, thalidomide and lenalidomide.

  • **Includes asthma, emphysema, chronic bronchitis, chronic obstructive pulmonary disease, pulmonary hypertension, interstitial lung disease, idiopathic pulmonary fibrosis, other lung diseases.

  • ††Includes belimumab, IL-1 inhibitors (anakinra, canakinumab, rilonacept), IL-6 inhibitors (tocilizumab, sarilumab, siltuximab), IL-12/IL-23 inhibitors (ustekinumab, guselkumab), IL-17 inhibitors (secukinumab, ixekizumab), eculizumab, mepolizumab and vedolizumab.

  • ‡‡Includes Novavax, Sinovac/Sinopharm, Sputnik V, Cansino, ‘not sure’ and ‘other’.

  • bDMARDs, biologic DMARDs; csDMARDs, conventional synthetic DMARDs; DMARDs, drug-modifying antirheumatic drugs; IL, interleukin; IVIG, intravenous immunoglobulin; JAK, Janus kinase inhibitors; NSAIDs, non-steroidal anti-inflammatory drugs; TNF, tumour necrosis factor.